+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Enhanced binding of tissue factor-microparticles to collagen-IV and fibronectin leads to increased tissue factor activity in vitro

Enhanced binding of tissue factor-microparticles to collagen-IV and fibronectin leads to increased tissue factor activity in vitro

Thrombosis and Haemostasis 109(1): 61-71

The role of tissue factor (TF)-containing microparticles in clot propagation has been established, but the ability of circulating microparticles to initiate coagulation has been disputed. However, TF-bearing microparticles, particularly endothelial-microparticles generated during disease, may interact with extracellular matrices which in turn can localise circulating TF to sites of injury. In order to examine this hypothesis in vitro , microparticles were isolated from human coronary artery endothelial cells transfected to overexpress TF, tumour-necrosis factor (TNF) α-treated cells or non-transfected cells lacking TF. The ability of microparticles to bind collagen-IV, fibronectin and fibrin was examined under static conditions and arterial shear rates (650 s⁻¹), and also in the presence of inhibitory antibodies against β1-, β3-, α3- and αv-integrins or an anti-TF antibody. TF-microparticles showed increases of up to 43% and 24% in adherence to collagen-IV and fibronectin, respectively, compared to control microparticles under shear flow. Furthermore, TF-containing microparticles, but not the transfected parent cells had increased levels of β1-integrin compared to TF-deficient microparticles. Pre-incubation of microparticles with a β1-integrin-blocking antibody counteracted the additional adhesion of TF-microparticles compared to control microparticles. Finally, adherence of TF microparticles to collagen-IV or fibronectin resulted in increased TF activity by concentrating TF onto the surface. In conclusion, the presence of TF within microparticles enhances the interactions of endothelial cell-derived microparticles with extracellular matrices in an integrin-dependent manner. Accumulation and localisation of these microparticles in turn results in the enhancement of TF activity. This may be an innate mechanism by which TF-bearing microparticles induce coagulation upon vascular injury.

(PDF emailed within 1 workday: $29.90)

Accession: 052982321

Download citation: RISBibTeXText

PMID: 23152142

Related references

Proteolysis of tissue factor pathway inhibitor-1 on circulating tissue factor bearing microparticles by thrombolysis in acute myocardial infarction is associated to an increased thrombin generation. European Heart Journal 24(Abstract Supplement): 579, August-September, 2003

Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis. Blood 96(10): 3452-3458, 2000

Increased platelet residual activity in patients treated with acetosalicylic acid is associated with increased tissue factor and decreased tissue factor pathway inhibitor plasma levels. International Journal of Cardiology 146(3): 479-481, 2011

Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. Journal of Thrombosis and Haemostasis 9(4): 759-766, 2011

Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 85(1): 121-129, 1995

Microparticle-associated tissue factor is recycled by endothelial cells resulting in enhanced surface tissue factor activity. Thrombosis and Haemostasis 110(5): 966-976, 2014

Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thrombosis and Haemostasis 101(6): 1147-1155, 2010

Increased tissue factor and tissue factor pathway inhibitor levels in the lungs of idiopathic pulmonary fibrosis patients associated with elevated procoagulant activity. Fibrinolysis & Proteolysis 12(SUPPL 1): 74, 1998

Fibronectin-adherent monocytes express tissue factor and tissue factor pathway inhibitor whereas endotoxin-stimulated monocytes primarily express tissue factor: physiologic and pathologic implications. Journal of Thrombosis and Haemostasis 5(7): 1493-1499, 2007

Increased monocytic tissue factor expression and activity after successful PTCA and stent in acute myocardial infarction is not downregulated by tissue factor pathway inhibitor. Circulation 98(17 SUPPL ): I453, Oct 27, 1998

Elevated Whole Blood Tissue Factor Procoagulant Activity in Diabetes Mellitus Vitamin E Inhibits Glucose Induced Tissue Factor Activity In Vitro. Blood 100(11): Abstract No 1931, November 16, 2002

PTRF (polymerase I and transcript-release factor) is tissue-specific and interacts with the BFCOL1 (binding factor of a type-I collagen promoter) zinc-finger transcription factor which binds to the two mouse type-I collagen gene promoters. Biochemical Journal 347 Pt 1: 55-59, 2000

Activity of Tissue Factor in Microparticles Produced in vitro by Endothelial Cells, Monocytes, Granulocytes, and Platelets. Biochemistry. Biokhimiia 81(2): 114-121, 2017

Fibroblast tissue factor: calcium and ionophore induce shape changes, release of membrane vesicles, and redistribution of tissue factor antigen in addition to increased procoagulant activity. Blood 84(2): 526-534, 1994

Differential ability of tissue factor antibody clones on detection of tissue factor in blood cells and microparticles. Thrombosis Research 130(3): 538-546, 2013